» Articles » PMID: 30868056

Histone Deacetylase 2 is Involved in DNA Damage-mediated Cell Death of Human Osteosarcoma Cells Through Stimulation of the ATM/p53 Pathway

Overview
Journal FEBS Open Bio
Specialty Biology
Date 2019 Mar 15
PMID 30868056
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor suppressor p53 is a short-lived nuclear transcription factor, which becomes stabilized and activated in response to a wide variety of cellular stresses. Around 50% of human cancer tissues carry mutations, and certain mutations contribute to chemoresistance. In the present study, we found that histone deacetylase 2 (HDAC2) acts as a co-activator of tumor suppressor p53 and participates in the early molecular events following DNA damage. Anti-cancer drug adriamycin (ADR) treatment induced cell death in -wild-type human osteosarcoma U2OS cells, and this was accompanied by a remarkable accumulation of p53 and γH2AX. gene silencing significantly decreased the sensitivity of U2OS cells to ADR and attenuated p53-dependent DNA damage responses, such as ADR-mediated phosphorylation of ataxia telangiectasia mutated (ATM) and p53, as well as accumulation of γH2AX and cleaved poly (ADP-ribose) polymerase. However, knockdown had a marginal effect on -null human lung cancer H1299 cells following ADR exposure. In contrast, forced expression of HA-HDAC2 promoted cell death and stimulated the transcriptional activity of p53. Moreover, p53 and HDAC2 were found to co-precipitate with ATM. Together, our present results strongly suggest that the p53-HDAC2 axis plays a vital role in the regulation of the DNA damage response and also contributes to chemosensitivity of cancer cells.

Citing Articles

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.


New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?.

Rapti V, Tsaganos T, Vathiotis I, Syrigos N, Li P, Poulakou G Vaccines (Basel). 2022; 10(10).

PMID: 36298472 PMC: 9611551. DOI: 10.3390/vaccines10101607.


Deacetylation of Transcription Factors in Carcinogenesis.

Halasa M, Adamczuk K, Adamczuk G, Afshan S, Stepulak A, Cybulski M Int J Mol Sci. 2021; 22(21).

PMID: 34769241 PMC: 8583941. DOI: 10.3390/ijms222111810.


Predictive Study of the Active Ingredients and Potential Targets of for the Treatment of Osteosarcoma via Network Pharmacology.

Gong Y, Fu S, Wei Z, Liu J Evid Based Complement Alternat Med. 2021; 2021:1480925.

PMID: 34194515 PMC: 8203350. DOI: 10.1155/2021/1480925.


Elucidation of the Hdac2/Sp1// axis as a modulator of cochlear apoptosis via / models of acute hearing loss.

Xie L, Zhou Q, Chen X, Du X, Liu Z, Fei B Mol Ther Nucleic Acids. 2021; 23:1093-1109.

PMID: 33614251 PMC: 7875768. DOI: 10.1016/j.omtn.2021.01.017.


References
1.
Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

2.
Grozinger C, Schreiber S . Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002; 9(1):3-16. DOI: 10.1016/s1074-5521(02)00092-3. View

3.
Tanaka T, Halicka H, Huang X, Traganos F, Darzynkiewicz Z . Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle. 2006; 5(17):1940-5. PMC: 3488278. DOI: 10.4161/cc.5.17.3191. View

4.
Wagner T, Brand P, Heinzel T, Kramer O . Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta. 2014; 1846(2):524-38. DOI: 10.1016/j.bbcan.2014.07.010. View

5.
Muller B, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J . Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013; 13:215. PMC: 3646665. DOI: 10.1186/1471-2407-13-215. View